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Summary
Adaptive designs have been proposed for ethical concerns, their characteristics,
especially in statistics, are widely investigated in the literature. In this thesis, we
investigate adaptive designs which direct the trials to an optimal dose level by using
Generalized Friedman’s Urn Model (GFU), considering the patients’ effect on the
probability of success for each dose. A generalized linear model(GLM) is employed
with consideration of the patients’ covariates and the dose levels simultaneously.
The limiting properties of the Maximum Likelihood Estimation(MLE), especially
its Central Limit Theorem (CLT) are established in the circumstance that the
response variables are dependent. The asymptotic properties of Urn composition
and allocation proportion are investigated. Simulations are conducted to verify
these properties.
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In any sequential medical experiment on a cohort of human beings, there is
an ethical imperative to provide the best possible medical care for the individual
patient. This ethical imperative may be compromised if a traditional randomiza-
tion scheme involving 50-50 allocation is used as accruing evidence to favor one
treatment over the other.
A case in point is reported by Conner et al. (1994) to evaluate the hypothesis
that the antiviral therapy AZT reduced the risk of maternal-to-infant HIV trans-
mission. A traditional randomization scheme was used to obtain equal allocation
to both AZT and placebo, resulting in 239 pregnant women receiving AZT and 238
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receiving placebo. The endpoint was whether the newborn infant was HIV-negative
or HIV-positive. The results of the trial were compelling: at the conclusion of the
trial, 60 newborns were HIV-positive in the placebo group and only 20 newborns
were HIV-positive in the AZT group. Three times as many infants on placebo have
received a death sentence by the transmission of HIV from their mothers. If they
had been given AZT, one could presume that many would have been saved. Given
the seriousness of the outcome of this study, it is reasonable to argue that 50-50
allocation was unethical. As accruing information favoring the AZT arm became
available, allocation probabilities should have been shifted from 50-50 allocation
proportional to the weight of evidence for AZT. Designs which attempt to do this
are called adaptive designs, response-adaptive designs or response-driven designs.
Adaptive design in clinical trials are schemes for patient allocation to treat-
ment, the goal of which is to place more patients on the better treatment based
on patient responses already accrued in the trials. For example, if there are two
treatments A and B, then when a patient is ready to be allocated to a treatment,
if treatment A appears to be more successful than treatment B, that patient would
have a greater than 50% chance of being allocated to treatment A. Adaptive designs
are attractive because they satisfy an ethical imperative of caring for the individual
patient in a group experiment, while allowing for the same group inference.
In statistics, sequential design is a subfield of experimental design which deals
with the appropriate sequential selection of design points. When design points are
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sequentially selected according to outcomes at previously selected design points,
such designs are called adaptive. Since future design point selection can rely on
information previously accrued, they can target an objective more accurately than
if design points are selected in the absence of information.
1.2 Urn Model
In adaptive designs, the allocation rules of patients in the trials are primary
concerns. The ethics of clinical trials not only need to derive information about
the effectiveness of the treatments, but to benefit the health of patients as well.
Urn models have been one technique(among many) used to incorporate accruing
data into the sequential design.
1.2.1 Play-the-Winner Rule
From the perspective of ethics, Zelen (1969) firstly explored the design meth-
ods to place more patients on the better treatment and proposed out the original
design called Play-the-Winner Rule. From then on, allocating patients sequen-
tially in clinical trials has been extensively explored in theoretical fields. In Zelen’s
formulation there are two treatments (say, A and B), patients enter the trial se-
quentially and are allocated to treatment A or B, and the trial outcome is success
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or failure depends only on the treatment given. A success on a particular treat-
ment generated a future trial on the same treatment assigned to the next patient.
A failure on a treatment generates a future trial on the alternate treatment. When
there exists delayed responses, i.e. the result of the treatment can not be obtained
until the next patient enters the trials, allocation is determined by tossing a fair
coin. In Play-the-Winner Rule, the allocation scheme is not random but determin-
istic, which may bias the trial in various ways. For example, if the experimenter
is in favor of treatment A and he knows or guesses which treatment will be the
next assignment, then he may introduce bias into the trial through the selection of
patients, this kind of bias is called selection bias. On the other hand, it does not
take the case of the delayed responses into consideration. However, this design can
be seen as a raw urn model implicitly and widened the researchers’ horizon to the
randomized urn models later on.
1.2.2 Randomized Play-the-Winner Rule
Wei and Durham (1978) propose the Randomized Play-the-Winner (RPW)
rule which keeps the spirit of the Play-the-winner rule in that it assigns more
patients to the better treatment. But this rule has the advantages that it is not
deterministic and is less vulnerable to experimental bias, it allows delayed response
by the patients. The formulation of the RPW rule is as follows: Assume there are
two treatments(say, A and B), with dichotomous response(success or failure). We
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start with u balls of each type in the urn. When a patient is ready for random-
ization, a ball is drawn and replaced, and the appropriate treatment is assigned.
If the response of the patient is a success, an additional β balls of the same type
are added to the urn and an additional α balls of the opposite type are added to
the urn. If the response was a failure, then an additional α balls of the same type
are added to the urn and additional β balls of the opposite type are added to the
urn. Wei and Durham compared the RPW with the traditional equal-allocation
rule and found that the latter can involve selection bias. The above RPW can be
denoted as RPW(u, α, β). Compared to the Play-the-Winner rule, RPW is a true
randomized urn model, which allows the delayed responses and take advantage of
randomization strategy.
1.2.3 Generalized Friedman’s Urn Model
A very important class of adaptive designs is one based on the generalized
Friedman’s urn (GFU) model (Athreya and Karlin (1968)), which has wide appli-
cations in clinical trials, bioassay and psychophysics.
Adaptive designs using the GFU model can be formulated as follows. As-
sume, initially, an urn contains K types of balls, denoted by Y0 = (Y01, ...Y0K),
respectively representing K treatments in a clinical trial, where Y0k denotes the
number of balls of type k, k = 1, ..., K. These treatments are to be sequentially
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assigned in n consecutive stages. At stage i, i = 1, ..., n, a ball is drawn from the
urn with replacement. If a ball of type k is drawn at the i-th stage, then the
treatment k is assigned to the patient i, k = 1, ..., K; i = 1, ..., n. Let ξ(i) de-
note a random variable associated with the i-th stage of the clinical trial, which
may include measurements on the i-th patient and the outcome of the treatment
at the i-th stage. Then additional Dk, q(i) balls of type q are added to the urn,
q = 1, ..., K, where Dk, q(i) is a function of ξ(i). This procedure is repeated to
the n-th stage. After n stages and generations, the urn composition is denoted
by the vector Yn = (Yn1, ..., YnK), where Ynk represents the number of type k
balls in the urn. Furthermore, we define Di = 〈〈Dk, q(i), k, q = 1, ..., K〉〉 and
Hi = 〈〈E(Dk, q(i)), k, q = 1, ..., K〉〉, i = 1, ..., n.(sometimes, the conditional ex-
pectation). The matrices Di’s are called adding rules and Hi’s are the generating
matrices.
We call the GFU model homogeneous if Hi = H for all i = 1, ..., n. For a
homogeneous GFU model, under the assumptions (i) Pr{Dk, q = 0, q = 1, ..., K} =
0 for every k = 1, ..., K and H is positive regular(i.e. Hm has positive entries for
some m > 0),Athreya and Karlin (1968) and Athreya and Ney (1972) prove the







where Nnk is the number of patients allocated to the k-th treatment after n stages.
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v = (v1, ...vK) is the left eigenvector of the largest eigenvalue λ of H. Let λ1 denote
the eigenvalue of the second largest real part, with corresponding right eigenvector
η. Furthermore, under additional assumption that λ > 2Re(λ1), Athreya and




′ → N(0, σ2) (1.3)
where σ2 is constant.
Wei (1979) first noted that the RPW rule could be formulated as a GFU model.
Let pi be the probability of success on treatment i = A,B,and qi = 1 − pi. The
RPW rule is a Generalized Friedman’s Urn with K = 2; the adding rule is given
by:
D =
 ξAβ + (1− ξA)α ξAα+ (1− ξA)β
ξBα+ (1− ξB)β ξBβ + (1− ξB)α

where ξi(i = A,B) = 1 or 0 represents success or failure of treatment i.
H =
 βpA + αqA αpA + βqA
αpB + βqB βpB + αqB

where H is a constant matrix and the maximal eigenvalue is simply the row sum
λ = α + β.
Thus, from (1.1) and (1.2), we can obtain results on the proportion of patients




a.s.→ vA = αpB + βqB
α(pA + pB) + β(qA + qB)
(1.4)
and the urn composition of type A balls as
YnA
YnA + YnB
a.s.→ vA = αpB + βqB
α(pA + pB) + β(qA + qB)
(1.5)
We note that (1.4) is increasing in β/α and tends to
qB
qA + qB
as β/α → ∞.
Therefore, if β is large with respect to α, we force the trial to put more patients
on the better treatment. But if β/α is too large, the RPW(u, α, β) becomes rather
deterministic and may allow unwanted bias in the trial.
1.2.4 Generalizations of GFU Model
Several generalizations of GFU model have been made in recent years. Among
them, the first principal one involves allowing the ball selected not to be replaced
or allowing some balls to be removed from the urn. Smythe (1996) defined the
Extended Po´lya Urn model (EPU) with
K∑
q=1
E(Dk, q) = c > 0, k = 1, ..., K (1.6)
namely, adding an expected constant total number of balls at each stage, but the
type k ball drawn does not have to be replaced, and in fact, additional type k balls
can be removed from the urn, subjected to (1.6) and a restriction is that one cannot
remove more balls of a certain type than are present in the urn (i.e., H is tenable).
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For the EPU, Smythe (1996) established the asymptotic normality of Yn and Nn
under the assumptions: (i) for each nonprincipal eigenvalues λj, λ > 2 Re(λj);
(ii) all eigenvalues are simple, and no two distinct complex eigenvalues have the
same real part, except for conjugate pairs; and (iii) the eigenvectors are linearly
independent, where Nn = (Nn1, ..., NnK) and Nnk is the number of times a ball of
type k drawn in the first n trials.
The second major generalization of the GFU model is the introduction of a
nonhomogeneous generating matrix, Hn, where the expected number of balls added
to the urn changes across draws. This is the model investigated by Bai and Hu
(1999), they assume there is a positive regular matrix H such that
∞∑
n=1
n−1||Hn −H||∞ <∞ (1.7)
In this case, the limiting results given in (1.1) and (1.2) remain hold.
From the above introduction of adaptive designs, the GFU model has been
playing a significant role in that it can skew the probabilities to favor the treatment
that has been the most effective thus far in the trial, thus making the randomization
strategy more attractive to physicians than traditional allocations.
We are interested in designs that provide information about dose that max-
imizes the probability of success, i.e. the optimal dose, while treating very few
subjects at dosages that have high risks of failure. The aim of this thesis research
is to find an optimal dose level for clinical trials through adaptive design using GFU
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scheme with consideration of the patients’ covariates. In the past literature, the
patient’s covariate, which actually having effect on the performance of the treat-
ment assigned to the patient, have not been taken into consideration. In Chapter
2, a generalized linear model is proposed with consideration of the patients’ covari-
ates and the dose levels simultaneously. The Maximum Likelihood Estimation is
used to estimate parameters. The asymptotic properties of the MLE,including the
law of large numbers and central limit theorem (CLT) are investigated. A theo-
rem regarding Urn composition is proved. In Chapter 3, a series of simulation is
conducted to verify the above results and to select the optimal dose in the circum-





2.1 Introduction to The New Model
Previously, the adaptive designs have not considered the patients’ covarients.
In those adaptive designs, the performance of treatments is equal for all patients.
However, in fact, the effectiveness of treatments should strongly relate to the pa-
tients’ covariates such as disease history, physical fitness, which will have great
effects on the performance of treatments. Here, we are going to take patients’
covariates and treatments (or dosage, dose level) into account simultaneously and
propose a generalized linear model based on GFU, which can assign more patients
to the better treatment only for their specific covariates.
Our model can be described as follows: suppose there areK dose levels denoted
11
as d1, d2, ..., dK . Let Xi for i = 1, ..., n be the i-th patient’s covariate, Zi be the dose
level randomly chosen from the K dose levels with certain probabilities. Also, for
k = 1, ..., K, let Iki = 1 if Zi = dk, and Iki = 0 otherwise. Assume that patient’s
response is dichotomous. Let Yi = 1 if the i-th patient’s response is a success,
0 otherwise. Define pi = Pr(Yi = 1|Zi, Xi) for i = 1, ..., n be the probability of
success of the i-th patient. Consider the following logistic model:
logitpi = α+ βZi + γZ
2
i + λXi i = 1, ..., n (2.1)
Define the allocation function: Fk, i(x), k = 1, ..., K for the i-th stage. We
assume that
Fk, 0 ≡ 1, k = 1, ..., K
We also assume that the response can be obtained before the next patient
enters the trials, i.e. there is no possibility of delayed response. After the response
of the i-th patient is obtained, we update the allocation function according to the
following equations:
Fk, i(x) = Fk, i−1(x) + [YiIk, i + (K − 1)−1(1− Yi)(1− Ik, i)]f(x, xi) (2.2)
where f(a, b) is a decreasing function of |a− b| (a,b are symmetric in f). We also
assume that Ea, b[(f(a, b))
2] < ∞. The updating rule implies that if the response
of the (i − 1)-th patient is successful, then we tend to allocate the i-th patient to
the same treatment if one has the covariate value near xi−1. Here adding a function
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f(x, xi) to the previous function Fk, i−1(x) can increase the weight of possibility of
allocating the i-th patient with the covariate near to the last covariate xi−1 to the
more successful dosage.
By(2.2),we have
Pr(Ik, i = 1) =
Fk, i−1(xi)∑K
l=1 Fl, i−1(xi)
where Ik, i = 1 if the i-th patient was allocated to dose k, 0 otherwise.
This new model can be seen as an urn model. Suppose an urn with K types
of balls. At the i-th stage, the urn composition (F1, i(x), ..., FK, i(x)) is a vector
of functions of x. When the new patient enters the trial, then one’s covariate xi+1
is measured, we plug xi+1 into the functions, thus we can get a vector with fixed
values: (F1, i(xi+1), ..., FK, i(xi+1)) for i = 1, ..., n. If the i-th response is successful
on treatment k, then another f(x, xi) number of type k balls will be added to the
urn, otherwise, (K−1)−1f(x, xi) number of balls will be added to every other type.
2.2 The Likelihood and Asymptotic Properties
of MLE
The Maximum Likelihood Estimation (MLE) can be used to estimate the pa-
rameters in (2.1). Let Y n = {Y1, ..., Yn} be the response history, Zn = {Z1, ..., Zn}
be the history of design point (treatment) assignment, Xn = {X1, ..., Xn} be the
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history of subjects’(patient) covariates.
The likelihood can be written as:
Ln(θ) = Ln{Y n, Zn, Xn, θ}
We assume that:
(1)the response depends on the selected design point, the subjects’ covariates,
and some parameter vector θ (suppose θ is a vector of dimension s);
(2)future design points are selected according to some function of the data from
the response history, design point assignment history and subjects’ covariates, but
independent of θ;
(3)subjects’ covariates are independent.
Consequently, the likelihood can be expressed as follows:
Ln(θ) = Ln{Y n, Zn, Xn; θ}
= L {Yn|Y n−1, Zn, Xn; θ}L{Zn|Y n−1, Zn−1, Xn; θ}
L {Xn|Y n−1, Zn−1, Xn−1; θ}Ln−1(θ)
= L {Yn|Zn, Xn; θ}L {Zn|Y n−1, Zn−1, Xn}L {Xn}Ln−1(θ)
The term L {Zn|Y n−1, Zn−1, Xn} is just the allocation function and is ancillary to
the likelihood as is the probability distribution of the covariates. Unwinding the
14





































By equating the derivative of the log-likelihood with respect to θ to equal 0,
we can obtain the maximum likelihood estimator for θ, we denote this estimator
as θˆn.
It should be noted that Y1, ...Yn are dependent random variables due to the
sequential design. Consequently, it is necessary to use martingale theory to prove
the usual asymptotic properties of maximum likelihood estimators. Ln(θ) ≡














where L0 = 1, a = 1, ..., s.
In Appendix 1, a theorem of the limiting results of MLE is proved for the
general stochastic process by imposing a certain regularity conditions.
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Consider the generalized linear model in the exponential family:
f(yi) = exp
{
yiηi − a(ηi) + b(yi)
φ
}
where ηi = h(w
T
i θ) (Nelder and Wedderburn,1972). With this model,
E(yi|wi) = a′(ηi); V ar(yi|wi) = a′′(ηi)φ.
For the moment, assume that the scale parameter φ is fixed. Liking to the
notation used in the previous sections, θ = (α β γ λ)T , wi = (1 zi z
2
i xi)
T are 4× 1






{yi − a′(ηi)}h′(wTi θ)wai (2.4)














P→ γab (as n→∞), a, b = 1, ..., 4, (2.5)

























P→ 0 (as n→∞), (2.7)






is consistent for θ, and n1/2(θˆ − θ)→ N(0,Γ−1).
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The theorem results directly from conditions(A1)-(A5) of Appendix 1. (A1)
and (A2) are standard regularity conditions that apply to exponential families.






















{h′(wTi θ)}2waiwbi{yi − a′(ηi)}2
)
which then can be written as the left-hand side of (2.5). Condition (2.6) implies
condition (A4) with δ = 1, and conditions (2.5) and (2.7), together with (A4),
implies (A6).
Let h(t) = t, a(η) = log(1 + eη), and φ = 1. Then h
′
= 1, h′′ = 0, and (2.7) is











P→ 0 (as n→∞)
and this follows since the summands are bounded in i. Condition (2.5) establishes









P→ γab (as n→∞) (2.9)
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2.3 Asymptotic properties of Urn composition
The asymptotic property of Urn composition is a main concern when investi-
gating statistically the Urn model.
From the model stated in Section 2.1, we have:
K∑
k=1




Let g(x) is the expectation of f(x, xi) with respect to Xi. Because X1, ..., Xn
are i.i.d. random variables, from the Law of Large Numbers, we have:∑n
i=1 f(x, xi)
n















→ Exg(x) ≡ g (2.11)
Denote Ak, i ≡ [YiIk, i + (K − 1)−1(1 − Yi)(1 − Ik, i)]f(x, xi) and let Fn ≡
σ{Y n, Xn+1, Zn} be the σ−field after n stages.Then,
Fk, n(x) = 1 +
n∑
i=1





















Ak, i − E
(
Ak, i
∣∣Fi−1),Fi, i = 1, ..., n} is a martingale difference because:
E
[




Let pki = 1 − qki be the probability of success if the i-th patient is allocated












+ (K − 1)−1
∑







[(K − 1)pki − qki]Fk, i−1(xi) +
∑K
l=1 qliFl,ı−1(xi)










[Kpki − 1]Fk, i−1(xi) +
∑K
l=1 qliFl, i−1(xi)





[Kpki − 1]Fk, i−1(xi) +
∑
l qliFl, i−1(xi)
(K − 1)[K + (i− 1)g(xi)] + δ1n
where
δ0 ≡ f(x, xi)Kpk1 +
∑K






(K − 1)−1f(x, xi)
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(Kpki − 1)Fk, i−1(xi) +
∑
l qliFl, i−1(xi)
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K + (i− 1)g(xi)
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≡ ∆0 +∆n +∆1n




























































where R1n, R2n denote the above two corresponding terms.
Let Rn ≡ ∆1n +∆2n −R2n, then:
∫
x
Fk, n(x) = 1 + ∆0 +R1n −R2n +∆1n +∆2n
= 1 +∆0 +R1n +Rn
= 1 +∆0 + ER1n + (R1n − ER1n) +Rn
where the expectation is with respect to Xi.
Suppose Cov[f(xi, xj), pi
∣∣Fi−1] = 0 for k = 1, ...K, j < i, then
Cov[Fk, i−1(xi), Kpi − 1]
= E
[
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(K − 1)(n− 1)

(K − 1)P1 Q2 · · · QK
Q1 (K − 1)P2 · · · QK
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .




















(K − 1)P1 Q2 · · · QK
Q1 (K − 1)P2 · · · QK
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Q1 Q2 · · · (K − 1)PK

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n− 1H)Fn−1 +∆Wn (2.13)
Assumption 1 Suppose that H is of non-negative entries and H
′
(transpose of
H)has the Jordan form decomposition
T−1H
′
T = J =

λ0 0 · · · 0
0 J1 · · · 0
. . . . . . . . . . . . . . .




λt 1 0 · · · 0
0 λt 1 · · · 0
. . . . . . . . . . . . . . . . . . .
0 0 · · · λt 1
0 0 0 · · · λt

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where λ0 = 1 is the unique maximum eigenvalue of H. Moreover, we assume
that the elements of the eigenvector v = (v1, ..., vK)
T associated with the positive




Theorem 2 As n→∞, we have the following asymptotic property:
Fk, n(x)/n
a.s.→ g(x)vk











for k = 1, ..., K.
See Appendix 2 for the Proof.




To verify the asymptotic results obtained is Chapter 2 and help with selection
of optimal dose, a series of simulations are conducted. R language is used to
conduct these simulations. A typical source code can be found in Appendix 3.
3.1 Algorithm
The algorithm can be described as the following procedures:
1 Set K=10 dose levels, they are dk = k/10, k = 1, ..., 10. Generate a sequence
of random variables Xi, i = 1, ..., n from a standard normal distribution or uniform
distribution over (0,1), then set some values for the parameters in (2.1).
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2 For the first trial, we allocate the patient to a certain dose level with equal
probability, i.e. Pr(Z1 = dk) = 0.1, k = 1, ..., K. In the following trials, for the
i-th patient, we plug the patient’s covariate Xi into the allocation function, then
generate the allocation function Ik, i, k = 1, ..., K with probabilities Pr(Ik, i = 1) =
Fk, i−1(xi)∑K
j=1 Fj, i−1(xi)
, k = 1, ..., K. The allocation function Fk, i(x), k = 1, ..., K is given
by (2.2).
3 By the logistic regression model, we can obtain the response of each patient:Yi(i =
1, ..., n) = 1 or 0 represents success or failure of patient i. Yi is generated with prob-
abilities Pr(Yi = 1) = pk, i if dose k is assigned to patient i.
4 According to (2.3), we can obtained MLE for the parameters the same as in
i.i.d case using the generated n responses. A circle is finished till now.
5 In order to investigate the asymptotic properties of MLE, we conduct N
circles to obtain N parameter estimations.
6 To investigate the asymptotic properties of Urn composition and select of
optimal dose, one circle with very large n is chosen.
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3.2 Simulation Results
3.2.1 Asymptotics of Maximum Likelihood Estimation (MLE)
Our investigations of normality will concentrate on the behavior of observa-
tions in one or two dimensions. As might be expected, it can be proved difficult
to construct a ”good” overall test of joint normality in more than two dimensions
because many aspects may be wrong. To some extent, we must pay a price for
concentrating on univariate and/or bivariate examinations of normality: We can
never be sure that we have not missed some feature that is revealed only in higher
dimensions. For convenience, we only check one dimension asymptotic behavior of
MLE. In R language, Shapiro-Wilk (1965) test is provided to test one dimension
normality. In Table 3.1-Table 3.4, we set α = −0.5, β = 10, γ = −10, λ = 2 (in
2.1), and let f(a, b) =
1
1 + |a− b| or f(a, b) =
1
1 + |a− b|2 and Xi’s be from Stan-
dard Normal Distribution or Uniform Distribution over (0,1). Let n = 500 and
N = 100. In these 4 cases, the performances of MLEs are good.The tests are not
significant as n is large(>200). A more detailed simulation results are presented in
Table 3.5 and Table 3.6.
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Table 3.1: f(a, b) =
1
1 + |a− b| , n = 500, N = 100, X ∼ N(0, 1).
Parameter True Value Mean Variance p-value
α -0.5 -0.49 0.301 0.18
β 10 10.16 4.537 0.37
γ -10 -10.26 3.597 0.64
λ 2 2.03 0.045 0.57
Table 3.2: f(a, b) =
1
1 + |a− b|2 , n = 500, N = 100, X ∼ N(0, 1).
Parameter True Value Mean Variance p-value
α -0.5 -0.55 0.238 0.31
β 10 10.18 3.865 0.42
γ -10 -10.15 3.049 0.53
λ 2 1.98 3.044 0.77
Table 3.3: f(a, b) =
1
1 + |a− b| , n = 500, N = 100, X ∼ U(0, 1).
Parameter True Value Mean Variance p-value
α -0.5 -0.62 0.368 0.67
β 10 10.24 5.806 0.24
γ -10 -10.20 4.549 0.20
λ 2 2.08 0.283 0.68
Table 3.4: f(a, b) =
1
1 + |a− b|2 , n = 500, N = 100, X ∼ U(0, 1).
Parameter True Value Mean Variance p-value
α -0.5 -0.58 0.363 0.70
β 10 10.33 6.040 0.80
γ -10 -10.28 4.750 0.46
λ 2 2.06 0.282 0.47
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Table 3.5: Comparisons on Different Situations-1,X ∼ N(0, 1).
Parameter TrueValue Mean VAR p-value
Case 1-1 n=200 N=100
α -0.5 -0.44 0.764 -2.950 2.457 -0.027 0.36
β 10 10.13 2.950 14.195 12.815 0.407 0.42
γ -10 -10.24 2.457 -12.815 12.092 -0.395 0.23
λ 2 2.08 -0.027 0.407 -0.395 0.111 0.78
Case 1-2 n=200 N=400
α -0.5 -0.54 0.557 -2.208 1.801 -0.011 0.75
β 10 10.35 -2.208 11.198 -10.020 0.316 0.22
γ -10 -10.39 1.801 -10.020 9.416 -0.334 0.12
λ 2 2.082 -0.011 0.316 -0.334 0.107 0.04
Case 1-3 n=500 N=100
α -0.5 -0.49 0.304 -1.042 0.783 0.020 0.18
β 10 10.16 -1.042 4.537 -3.888 0.031 0.37
γ -10 -10.26 0.783 -3.888 3.597 -0.064 0.64
λ 2 2.02 0.020 0.031 -0.064 0.045 0.57
Case 1-4 n=500 N=400
α -0.5 -0.48 0.245 -0.945 0.763 0.005 0.43
β 10 10.04 -0.945 4.479 -3.921 0.063 0.68
γ -10 -10.07 0.763 -3.921 3.594 -0.069 0.77
λ 2 2.04 0.005 0.063 -0.069 0.037 0.12
Case 1-5 n=1000 N=100
α -0.5 -0.54 0.127 -0.534 0.458 -0.008 0.75
β 10 10.11 -0.534 2.652 -2.395 0.074 0.27
γ -10 -10.10 0.458 -2.395 2.238 -0.072 0.34
λ 2 2.01 -0.008 0.074 -0.072 0.021 0.09
Case 1-6 n=1000 N=400
α -0.5 -0.51 0.099 -0.396 0.330 0.000 0.78
β 10 10.05 -0.396 2.009 -1.823 0.045 0.19
γ -10 -10.04 0.330 -1.823 1.730 -0.046 0.11
λ 2 2.01 0.000 0.045 -0.046 0.018 0.14
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Table 3.6: Comparisons on Different Situations-2,X ∼ U(0, 1).
Parameter TrueValue Mean VAR p-value
Case 2-1 n=200 N=100
α 1 1.17 0.902 -3.232 2.579 0.052 0.085
β 8 7.82 -3.232 16.500 -14.686 -0.022 0.396
γ -8 -7.85 2.579 -14.686 13.772 0.033 0.457
λ 1 1.031 0.052 -0.022 0.033 0.105 0.996
Case 2-2 n=200 N=400
α 1 1.00 0.934 -3.459 2.736 0.029 0.001
β 8 8.436 -3.459 16.475 -14.251 0.093 0.660
γ -8 -8.449 2.736 -14.251 12.878 -0.100 0.539
λ 1 1.03 0.029 0.093 -0.100 0.076 0.030
Case 2-3 n=500 N=100
α 1 1.05 0.289 -1.060 0.867 0.029 0.809
β 8 8.00 -1.060 5.425 -4.893 -0.040 0.760
γ -8 -8.04 0.867 -4.893 4.626 0.038 0.975
λ 1 1.04 0.029 -0.040 0.038 0.031 0.070
Case 2-4 n=500 N=400
α 1 0.97 0.306 -1.164 0.915 0.001 0.57
β 8 8.39 -1.164 5.735 -4.956 0.092 0.44
γ -8 -8.39 0.915 -4.956 4.491 -0.089 0.41
λ 1 1.03 0.001 0.092 -0.089 0.029 0.25
Case 2-5 n=1000 N=100
α 1 1.02 0.143 -0.527 0.409 0.002 0.25
β 8 7.92 -0.527 2.752 -2.357 0.053 0.09
γ -8 -7.92 0.409 -2.357 2.110 -0.050 0.20
λ 1 1.00 0.002 0.053 -0.050 0.013 0.75
Case 2-6 n=1000 N=400
α 1 1.01 0.181 -0.675 0.531 0.002 0.83
β 8 7.97 -0.675 3.218 -2.77 0.036 0.23
γ -8 -7.96 0.531 -2.773 2.501 -0.034 0.30
λ 1 1.01 0.002 0.036 -0.034 0.014 0.50
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3.2.2 Asymptotics of Urn Composition and Allocation Pro-
portion
By theorem 2,we know that the Urn composition converge to an eigenvector
described in Assumption 1. Table-3.7 gives the result as α = −0.5, β = 10, γ =
−10, λ = 2, f(a, b) = 1
1 + |a− b| , X ∼ N(0, 1):
Table 3.7: Urn composition and allocation proportion Convergence, n=20,000






Ik, i g(x)vk Fk, n(x)/n
0.1 0.0700 0.0713 0.074 0.0336 0.0343
0.2 0.0885 0.0956 0.087 0.0425 0.0460
0.3 0.1079 0.0917 0.101 0.0518 0.0441
0.4 0.1309 0.1280 0.123 0.0629 0.0616
0.5 0.1423 0.1345 0.135 0.0684 0.0647
0.6 0.1299 0.1311 0.124 0.0624 0.0630
0.7 0.1117 0.1142 0.114 0.0537 0.0549
0.8 0.0948 0.1081 0.108 0.0455 0.0520
0.9 0.0718 0.0745 0.076 0.0345 0.0358
1.0 0.0520 0.0507 0.055 0.0249 0.0244
From the above table, we can find that, for a random generated value x (for
convenience, the last patient’s covariate is used), both of the Urn composition and
allocation proportion near to v as n is very large. We can also see that dose level
0.5 is the optimal dose with its highest Urn composition and allocation proportion,
thus, make more patients be allocated to the optimal dose.
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3.2.3 Selection of Optimal Dose
The patients’ covariates may have, in certain extent, positive or negative effects
on the probability of success of the dose level assigned to this patient. If the
coefficient λ in the GLM is relatively great, the effects on the probabilities of success
will adverse the selection of optimal dose, because of the randomness of the patients’
covariates. Let n be very large(>1,000), this randomness can be counteracted if
each dose is drawn enough times. Taking average of the probabilities of success for
each dose over the number of patients allocated to, we obtain an approximation
of the probability of success for each dose. Table-3.8 is an example in which we
use: α = −0.5, β = 10, γ = −10, λ = 2, f(a, b) = 1
1 + |a− b| , X ∼ N(0, 1), n =
20, 000. The probabilities of success for each dose when taking patients’ covariates
into account, still favor the optimal dose we prescribed when not considering the
patients’ effects. Also, the number of times of allocation has the same trend with
the probabilities of success and shows that this model can actually take the patients’
effects into account and give an ethical concern. The probabilities of success for
each dose when taking patients’ covariates into account have, on average, the same
trend as without patients’ effect. This can be seen more clearly in Figure-3.1, where
the solid line is the probabilities of success without effect of patients’ covariates and
the dots are the probabilities of success with effect of patients’ covariates.
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Table 3.8: The effect of patients on the dose probability success.
DoseLevel 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Prob.ofSucc. 0.559 0.651 0.714 0.764 0.783 0.762 0.724 0.674 0.570 0.406
No. of Alloc. 1481 1749 2024 2467 2702 2477 2279 2179 1527 1115
Figure 3.1: The Effect of Patients’ Covariates on Dose Selection


























The main results of this assay are the asymptotic properties of Urn compo-
sition and allocation proportion in the circumstance of considering the patients’
covariates’ effects on the adding rule and the probability of success for each dose.
The ethic imperative are given consideration without affecting the statistical in-
ference of the model. As a result, this model places more patients to the optimal
dose and lowers the patients’s exposition to dose level with high risks of failure.
In our model, the generating matrix is in fact f(x, xi)H
′
. If we think that f(x, xi)
is associated with a weight to increase the probabilities of the allocating the i-th
patient with the covariate near to the last covariate xi−1 to the more successful
dosage, then H
′
plays a role as a ”generating matrix” as is in the GFU model. The
asymptotic properties of Urn composition and allocation proportion are related to
the unit eigenvector of the maximal eigenvalue of H, as is in the usual GFU case
without considering the patients’ covariates.
35
Appendix 1
Let Fn be the σ-field generated by the stochastic process through stage n
(Fn ≡ σ{Y n, Xn, Zn},in this thesis, denoting Fn ≡ σ{Y n, Xn+1, Zn} is suitable),
and define the conditional expectation of · with respect to Fn to be En(·) and the
conditional variance to be V arn(·). We will suppose there exists an open subset
Ω0 of the parameter space Ω containing the true parameter.
We impose the following regularity conditions on the likelihood:
(A1)
∫
Ln(y1, ..., yn; θ)dyn can be partially differentiated twice with respect to θ
under the integral sign and the first partials have finite moments of order 2+ δ for
some δ > 0.
(A2) For almost all y1, ..., yn, Ln(θ) admits all third partial derivatives, and the
absolute values of the third partials (with respect to θa, θb, θc) are bounded by a
function Mn(y1, ..., yn) for all θ ∈ Ω0. We assume Mabc ≡ sup
n
Mn(y1, ..., yn) is
integrable.
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Ui(θ)} P→ γab(θ) (as n→∞)
where γab(θ) is a nonrandom function of θ, for all θ ∈ Ω0.






Ui(θ)}2+δ P→ 0, (as n→∞)
for all θ ∈ Ω0.







P→ −γab(θ) (as n→∞)
for all θ ∈ Ω0, where γab(θ) is defined in (A3).
Define Γ(θ) to be an s × s matrix with elements γab(θ), where the γab’s are
defined in the condition (A3). Let θˆn ≡ (θˆ1n, ..., θˆsn) be a MLE for θ. We have the
following theorem:
Theorem 3 If conditions(A1)-(A5) are satisfied, then a consistent MLE θˆn exists
and the vector n1/2(θˆn − θ) is asymptotically multivariate normal with mean zero
and variance-covariance matrix [Γ(θ)]−1, provided the inverse exists.
Proof: Let Ln(θ) ≡ logLn(θ) =
n∑
i=1
Ui(θ) be the log-likelihood, Suppose θ0 is the
true parameter,using Taylor’s Expansion, we have:






where L′n is a s× 1 vector and L′′n is a s× s matrix, θ1 is a vector among two balls
with radii ||θ0|| and ||θˆn||.
Then























































,Fn, n ≥ 1
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for θ ∈ Ω0.















Ln(θ2)(θ1 − θ0) (4.5)





















Ln(θ1) is bounded in probability if we let ||θ1−θ0|| be less than some
constant. Therefore, in (4.4)
θˆn − θ0 P→ 0 (4.6)
Considering the consistence of θˆn, as n→∞, we have θ1 − θ0 P→ 0. Therefore, the
















The proof is complete.
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Appendix 2
Proof of Theorem 2:
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(Kpkj − 1)Fk, j−1(xj) +
∑
l qljFl, j−1(xj)




(Kpkj − 1) +
∑




(K − 1)(j − 1)
]
− K













K + (j − 1)g(xj)
]








Ak, j − E(Ak, j
∣∣∣Fj−1)]
















































(1, 1, ..., 1)
Thus,
e1T




Suppose f is bounded by 0 < m < f < M, (m,M are constants), then the
second term of ∆Wk, j has order O(j







[f(xj, xu) − g(xj)], then has order O(j−1/2). The summation of the





[f(xj, xu) − g(xu)], has order O(j−c) for
some constant c > 0 under a certain assumption on g(x). The summation of the
last term under k, is 0.
Thus, (1, 1, ..., 1)∆Wj, k has order O(j




































as n > i → ∞. Since each element of T−1Fn/n is bounded, we conclude that
T−1Fn/n must converge to a limit, say z, satisfying z = e
′
1e1z. This implies that
z ∝ e′1. It follows that
Fn/n→ CTe′1 = Cv
C is a constant.By(2.11),C = g.
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[K + (i− 1)g(xi)]g(xi)
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[K + (i− 1)g(xi)]g(xi)
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+ δ1n + δ2n























a.s.→ (K − 1)−1Exif(x, xi)
[





= (K − 1)−1g(x)
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i− 1 − g(xi)vl
)]
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i− 1 , i = 2, ..., n
}
is a martingale difference, and
f(x, xi)
g(xi)
is bounded, the first term is therefore o(n), the second, by LLN, is o(n), the




[K + (i− 1)g(xi)]g(xi)






























The proof is complete.
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Appendix 3
Simulation Source Code: A Typical Example
options(expressions=100000)
N<-400 #No. of Circles
n<-1000 #No.of Patients in Each Circle




for(j in 1:N) {
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P<-I #Probability of Success Array














for(i in 2:n) { urn<-rep(0,10)
# f<-rep(1,10)
# for(l in 1:(i-1))
# {for(k in 1:10)
# {f[k]<-f[k]+(y[l,j]*I[k,l]+(1-y[l,j])*(1-I[k,l])/9)/(1+abs(x[i]-x[l]))}























































for (k in 1:10) {
for (i in 1:w) { if(pro[i,2]==k)
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